Oral Ozanimod 72-week Phase II outcomes from RADIANCE Trial
New Jersey based Biopharmaceutical Company Celgene Corporation has reported 72-week outcomes from the RADIANCE phase II trial of ozanimod, an
Read more
Clinical Research Society
International Society for Clinical Research and Translational Medicine